High-intermediate risk defined as two or more of: T2c, Gleason 7 OR PSA 10-20ng/ml,
High-risk prostate cancer, defined as at least one of: T3, Gleason 8-10, OR PSA \> 20 ng/mL
Willing to give informed consent to participate in this clinical trial
Able and willing to complete EPIC, PORPUS and EQ-5D questionnaires
You may not be if
Prior pelvic radiotherapy
Contraindication to radical prostate radiotherapy e.g. connective tissue disease or inflammatory bowel disease
Anticoagulation medication (if unsafe to discontinue for fiducial insertion)
Diagnosis of bleeding diathesis
Poor baseline urinary function defined as International Prostate Symptom Score (IPSS) \>20
Evidence of castrate resistance (defined as PSA \< 3 ng/ml while testosterone is \< 0.7nmol/l. Patients could have been on combined androgen blockade but are excluded if this was started due to PSA progression.
Definitive extrapelvic nodal or distant metastatic disease on staging investigations.
Hip prosthesis
Clareo Health | 5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:
